News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
197 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53928)
2023 (42564)
2024 (37441)
2025 (33091)
2026 (15754)
Month
January (2433)
February (2866)
March (3029)
April (3115)
May (3357)
June (954)
Day
1 (65)
3 (19)
4 (205)
5 (197)
6 (190)
7 (229)
8 (170)
10 (33)
11 (150)
12 (194)
13 (208)
14 (261)
15 (58)
17 (52)
18 (160)
19 (145)
20 (146)
21 (119)
22 (102)
24 (37)
25 (10)
26 (177)
27 (191)
28 (158)
29 (80)
31 (1)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
Day
1
3
4
5
6
7
8
10
11
12
13
14
15
17
18
19
20
21
22
24
25
26
27
28
29
31
Manufacturing
Sertraline manufacturer recalls antidepressant batch after UK packaging mix-up
A subsidiary of Indian drugmaker Hetero Group mistakenly packaged two types of antidepressants in packs of sertraline, potentially posing risks to patients.
May 5, 2026
·
2 min read
·
Nick Paul Taylor
Insights
IPF draws investor heat as biotechs target fibrosis halt, better tolerability
Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis in other organs next
May 5, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Government
FDA uncertainty persists as search for Prasad successor at CBER drags on
The FDA is reportedly down to a handful of final candidates to lead CBER, with a potential selection expected in the coming month or two. For now, the appointment of acting director Katherine Szarama has not allayed the industry’s concerns.
May 5, 2026
·
2 min read
·
Tristan Manalac
Earnings
Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution
While some analysts may regard Vertex Pharmaceuticals’ first quarter results as “unremarkable,” BMO Capital Markets wrote on Monday, the second half of 2026 could be big for the biotech, with the potential approval of IgAN therapy povetacicept.
May 5, 2026
·
2 min read
·
Tristan Manalac
Obesity
Foundayo’s liver failure blip weighs down Lilly shares but analysts unconcerned
The selloff in Eli Lilly’s shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety profile of Foundayo remains favorable.
May 5, 2026
·
2 min read
·
Tristan Manalac
MASH
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead
Madrigal Pharmaceuticals has licensed from Arrowhead Pharmaceuticals an RNA interference candidate that targets a genetic mutation present in around 30% of patients with MASH.
May 5, 2026
·
2 min read
·
Tristan Manalac
Earnings
Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat
Despite the continued decline of Pfizer’s COVID-19 products, shares stayed stable on Tuesday morning after the New York pharma reported a first quarter beat, which was led by Eliquis and Ibrance.
May 5, 2026
·
2 min read
·
Annalee Armstrong
Earnings
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in
As Q1 earnings arrive, three biotechs have big quarters ahead, with two—Amylyx and Neumora Therapeutics—betting at least partly on novel assets for obesity.
May 5, 2026
·
5 min read
·
Heather McKenzie
Layoffs
BioNTech moves to close multiple manufacturing plants, affecting 1,860 jobs
The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.
May 5, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
Pfizer is a 2029 story but Q126 lays foundation for growth
A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.
May 5, 2026
·
3 min read
·
Annalee Armstrong
1 of 20
Next